Tenaya Therapeutics Statistics
Total Valuation
TNYA has a market cap or net worth of $148.32 million. The enterprise value is $62.18 million.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, after market close.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TNYA has 217.00 million shares outstanding. The number of shares has increased by 80.34% in one year.
| Current Share Class | 217.00M |
| Shares Outstanding | 217.00M |
| Shares Change (YoY) | +80.34% |
| Shares Change (QoQ) | +7.16% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 27.35% |
| Float | 166.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.84, with a Debt / Equity ratio of 0.09.
| Current Ratio | 6.84 |
| Quick Ratio | 6.51 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -83.84% and return on invested capital (ROIC) is -48.50%.
| Return on Equity (ROE) | -83.84% |
| Return on Assets (ROA) | -43.72% |
| Return on Invested Capital (ROIC) | -48.50% |
| Return on Capital Employed (ROCE) | -70.98% |
| Weighted Average Cost of Capital (WACC) | 20.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.29M |
| Employee Count | 70 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.96% in the last 52 weeks. The beta is 3.22, so TNYA's price volatility has been higher than the market average.
| Beta (5Y) | 3.22 |
| 52-Week Price Change | +20.96% |
| 50-Day Moving Average | 0.73 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 44.64 |
| Average Volume (20 Days) | 5,874,532 |
Short Selling Information
The latest short interest is 25.25 million, so 11.64% of the outstanding shares have been sold short.
| Short Interest | 25.25M |
| Short Previous Month | 23.55M |
| Short % of Shares Out | 11.64% |
| Short % of Float | 15.14% |
| Short Ratio (days to cover) | 4.17 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -93.33M |
| Pretax Income | -90.60M |
| Net Income | -90.60M |
| EBITDA | -84.90M |
| EBIT | -93.33M |
| Earnings Per Share (EPS) | -$0.59 |
Full Income Statement Balance Sheet
The company has $100.55 million in cash and $10.83 million in debt, with a net cash position of $89.72 million or $0.41 per share.
| Cash & Cash Equivalents | 100.55M |
| Total Debt | 10.83M |
| Net Cash | 89.72M |
| Net Cash Per Share | $0.41 |
| Equity (Book Value) | 123.27M |
| Book Value Per Share | 0.57 |
| Working Capital | 90.15M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$68.26 million and capital expenditures -$618,000, giving a free cash flow of -$68.88 million.
| Operating Cash Flow | -68.26M |
| Capital Expenditures | -618,000 |
| Depreciation & Amortization | 8.44M |
| Net Borrowing | n/a |
| Free Cash Flow | -68.88M |
| FCF Per Share | -$0.32 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TNYA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -80.34% |
| Shareholder Yield | -80.34% |
| Earnings Yield | -59.64% |
| FCF Yield | -45.35% |
Analyst Forecast
The average price target for TNYA is $5.33, which is 679.81% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.33 |
| Price Target Difference | 679.81% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |